Navigating 10 Analyst Ratings For Hims & Hers Health
Portfolio Pulse from Benzinga Insights
Analysts have provided mixed ratings for Hims & Hers Health (NYSE:HIMS) over the past quarter, with a notable increase in the average 12-month price target to $15.1. The company's financials show strong revenue growth, net margin, ROE, ROA, and debt management.
May 22, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have mixed ratings for Hims & Hers Health, with an increased average price target of $15.1. The company's financials are strong, with significant revenue growth and excellent ROE and ROA.
The increase in the average price target and strong financial metrics such as revenue growth, net margin, ROE, and ROA suggest a positive short-term impact on HIMS stock. The mixed analyst ratings indicate some uncertainty, but the overall financial health of the company is strong.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100